Priya Nanduri

Priya Nanduri, PhD has a diverse work experience in the biotechnology and pharmaceutical industries. Priya is currently working as a Senior Director of Business Development at Cerevel Therapeutics. Prior to this, they served as an Investor Relations Senior Director at Sanofi from January 2022 to February 2023. Priya also held positions at Translate Bio, where they were the Director of Corporate Development and Alliance Management from March 2021 to January 2022, and the Associate Director of Corporate Development from October 2018 to March 2021. Before that, Priya worked as a Consultant at Alacrita Consulting, specializing in business development assignments for the biotech and pharma industries from April 2015 to October 2018. Priya has also worked as a Business Development and Licensing Manager at BerGenBio AS from August 2017 to August 2018. Priya's early career involved research roles, including serving as a Graduate Research Assistant at Duke University from August 2010 to March 2015, where they contributed to important studies on protein degradation pathways and neurodegenerative diseases. Priya also worked as a Clinical Research Coordinator at the Barbara Davis Center for Childhood Diabetes, where they managed research studies related to autoimmune diseases from June 2009 to June 2010.

Priya Nanduri, PhD, has an extensive education background in the field of pharmacology and toxicology. Priya completed their Bachelor's Degree in Biochemistry, Molecular Biology, and Psychology from the University of Denver, which they attended from 2005 to 2009. Following their undergraduate studies, Priya pursued a Doctor of Philosophy (PhD) in Pharmacology and Toxicology at Duke University School of Medicine, where they were enrolled from 2010 to 2015. Additionally, Priya has an additional certification in Molecular Toxicology from Duke University. The specific month and year of obtaining this certification are not provided.